Infants of Diabetic Mother

1. Introduction & Pathophysiology

• Definition: Neonate born to a mother with pre-existing diabetes (Type 1 or 2) or gestational diabetes (GDM).
• Core Pathophysiology (Pedersen Hypothesis):

graph TD
    subgraph Maternal_Environment ["Maternal Environment"]
    A["Maternal Uncontrolled Diabetes"] -->|"Hyperglycemia"| B("Maternal High Blood Glucose")
    M_Insulin["Maternal Insulin"] -.->|"Does NOT Cross Placenta"| C
    end

    B -->|"Glucose Crosses Placenta Freely"| C("Fetal Hyperglycemia")

    subgraph Fetal_Environment ["Fetal Environment"]
    C -->|"Stimulates"| D("Fetal Pancreatic Beta-Cell Hyperplasia")
    D -->|"Overproduction"| E("Fetal Hyperinsulinemia")
    
    E -->|"Insulin = Growth Factor"| F["Macrosomia / Organomegaly"]
    F -->|"Risk of"| F1["Birth Trauma / Shoulder Dystocia"]

    E -->|"Increased Metabolic Rate"| G["Fetal Tissue Hypoxia"]
    G -->|"Increased Erythropoietin"| H["Polycythemia / Hyperviscosity"]
    H -->|"Breakdown of RBCs"| H1["Hyperbilirubinemia"]

    E -->|"Antagonizes Cortisol"| I["Delayed Surfactant Maturation"]
    I -->|"Risk of"| I1["Respiratory Distress Syndrome"]
    end

    subgraph Postnatal_Event ["Birth: Cord Clamping"]
    E -->|"Persistent Hyperinsulinemia"| J{"Glucose Supply Interrupted"}
    J -->|"Insulin remains High"| K["Neonatal Hypoglycemia"]
    end

    classDef critical fill:#f96,stroke:#333,stroke-width:2px;
    class K,H,F critical;

• Maternal Hyperglycemia $\to$ Fetal Hyperglycemia (transplacental).
• Fetal pancreatic $\beta$-cell hyperplasia $\to$ Fetal Hyperinsulinemia.
• Postnatal separation from placenta $\to$ interruption of glucose supply + persistent hyperinsulinemia $\to$ Hypoglycemia.
• Hyperinsulinemia acts as a fetal growth hormone $\to$ Macrosomia/Organomegaly.
• Fetal metabolic demand $\to$ Intrauterine Hypoxia $\to$ increased Erythropoietin $\to$ Polycythemia.

2. Metabolic Complications

A. Hypoglycemia (Most Common)

• Definition: Blood glucose < 40 mg/dL (plasma glucose < 45 mg/dL) irrespective of age, though operational thresholds vary.
• Timing:
  • Onset usually within 1-2 hours of life.
  • Rarely occurs after 12 hours (range 0.8–8.5 hours).
• Mechanism: Transient Hyperinsulinism (Acquired).
• Clinical Features:
  • Often asymptomatic.
  • Neurogenic: Jitteriness, tremors, sweating, tachycardia, pallor.
  • Neuroglycopenic: Lethargy, poor suck, weak cry, apnea, cyanosis, seizures, coma.
• Screening Protocol:
  • Target: All IDMs are high-risk.
  • Schedule: 2, 6, 12, 24, 48, and 72 hours of life.
  • Method: Point-of-care strip (screening) followed by laboratory confirmation if low.
• Management (Algorithm):
  • Asymptomatic (20–40 mg/dL): Trial of oral feeds (Breast milk preferred); recheck in 1 hour. If still <40 mg/dL $\to$ IV fluids.
  • Symptomatic or <20 mg/dL:
    • Bolus: 2 ml/kg of 10% Dextrose.
    • Maintenance: IV Glucose infusion @ 6–8 mg/kg/min.
    • Titration: Increase by 2 mg/kg/min (max 12 mg/kg/min) to maintain BGL > 50 mg/dL.
  • Resistant Hypoglycemia: If unstable despite GIR > 12 mg/kg/min, suspect other causes or severe hyperinsulinism; may require Hydrocortisone, Diazoxide (caution in SGA), or Octreotide.

B. Hypocalcemia & Hypomagnesemia

• Hypocalcemia: Usually occurs within first 24–72 hours due to functional hypoparathyroidism and maternal hypomagnesemia.
• Hypomagnesemia: Caused by maternal renal wasting of magnesium; correlates with severity of hypocalcemia.

3. Hematological Complications

A. Polycythemia & Hyperviscosity Syndrome

• Definition: Venous hematocrit $\ge$ 65% or Hb > 22 g/dL.
• Incidence: Occurs in ~15% of term SGA/LGA infants; risk increased in IDM.
• Pathophysiology: Fetal hypoxemia (placental insufficiency or high metabolic rate) $\to$ increased erythropoiesis.
• Clinical Features:
  • Cutaneous: Plethora (ruddy complexion), cyanosis.
  • CNS: Lethargy, jitteriness, seizures, infarcts.
  • Cardiopulmonary: Tachypnea, tachycardia, respiratory distress, cardiomegaly (pulmonary plethora).
  • GI: Poor feed, vomiting, Necrotizing Enterocolitis (NEC).
  • Renal: Oliguria, renal vein thrombosis.
  • Metabolic: Hypoglycemia, jaundice.
• Screening: Check hematocrit at 2 hours; repeat at 6, 12, 24, 48 hours if indicated.
• Management:

graph TD
    A["Start: Venous Hematocrit >= 65%"] --> B{"Exclude Dehydration"}
    B -- "Dehydrated?" --> C["Correct Dehydration & Re-measure Hct"]
    C --> A
    B -- "Not Dehydrated" --> D{"Symptomatic?"}

    D -- "Yes" --> E["Partial Exchange Transfusion PET"]
    E --> F["Target Hct: 55%"]

    D -- "No" --> G{"Check Hct Level"}
    
    G -- "Hct >= 75%" --> E
    G -- "Hct 70-74%" --> H["Conservative Management"]
    H --> I["Hydration / Extra Feeds +20ml/kg"]
    I --> J["Monitor Hct & Symptoms"]
    
    G -- "Hct 65-69%" --> K["Observation"]
    K --> L["Monitor for Symptoms & Re-check Hct"]

    style E fill:#f96,stroke:#333,stroke-width:2px
    style A fill:#bbf,stroke:#333,stroke-width:2px

• Asymptomatic:
  • Hct 65–69%: Monitor.
  • Hct 70–74%: Hydration (Feed/IV) to encourage hemodilution
  • Hct $\ge$ 75%: Partial Exchange Transfusion (PET).
  • Symptomatic (Hct > 65%): Partial Exchange Transfusion (PET).
  • PET Details:
    • $$volumeofbloodtobeexchanged=\frac{bloodvol\times (observeHct-DesiredHct)}{ObservedHct}$$
    • Desired Hct: 55%. Fluid: Normal Saline.

B. Hyperbilirubinemia

• Secondary to polycythemia (increased RBC mass breakdown) and immature hepatic conjugation.

C. Thrombocytopenia

• Mild, transient; associated with polycythemia/hyperviscosity.

4. Respiratory Complications

• Respiratory Distress Syndrome (RDS): Delayed surfactant maturation due to antagonism of cortisol by insulin.
• Transient Tachypnea of Newborn (TTN): Common in infants delivered via elective CS (associated with macrosomia).

5. Congenital Anomalies (Embryopathy)

• Occurs due to hyperglycemia during organogenesis (First Trimester).
• Cardiac: Hypertrophic Cardiomyopathy (septal hypertrophy - transient), Transposition of Great Arteries (TGA), VSD.
• CNS: Neural tube defects, Anencephaly.
• Skeletal: Caudal Regression Syndrome (Sacral Agenesis) – most specific to IDM.
• Gastrointestinal: Small Left Colon Syndrome, Situs Inversus.
• Renal: Renal vein thrombosis (associated with polycythemia).

6. Growth Abnormalities

• Macrosomia (LGA): Birth weight > 90th percentile or > 4000g. Risk of birth trauma (shoulder dystocia, Erb’s palsy, clavicle fracture) and asphyxia.
• IUGR (SGA): Seen in mothers with severe diabetic vasculopathy (placental insufficiency).

7. Long-term Outcome

• Neurodevelopment:
  • Symptomatic hypoglycemia linked to white matter abnormalities and executive function deficits.
  • Polycythemia-associated hyperviscosity may cause micro-infarcts but PET benefits on long-term outcome are debated.
• Metabolic: Increased risk of childhood obesity and early-onset Type 2 Diabetes (Metabolic programming).